Myocardial protection evoked by hyperoxic exposure involves signaling through nitric oxide and mitogen activated protein kinases

Hyperoxic exposure in vivo (> 95% oxygen) attenuates ischemia-reperfusion injury, but the signaling mechanisms of this cardioprotection are not fully determined. We studied a possible role of nitric oxide (NO) and mitogen activated protein kinases (MAPK) in hyperoxic protection. Mice (n = 7-9 in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Basic research in cardiology 2007-07, Vol.102 (4), p.318-326
Hauptverfasser: Ruusalepp, Arno, Czibik, Gabor, Flatebø, Torun, Vaage, Jarle, Valen, Guro
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 326
container_issue 4
container_start_page 318
container_title Basic research in cardiology
container_volume 102
creator Ruusalepp, Arno
Czibik, Gabor
Flatebø, Torun
Vaage, Jarle
Valen, Guro
description Hyperoxic exposure in vivo (> 95% oxygen) attenuates ischemia-reperfusion injury, but the signaling mechanisms of this cardioprotection are not fully determined. We studied a possible role of nitric oxide (NO) and mitogen activated protein kinases (MAPK) in hyperoxic protection. Mice (n = 7-9 in each group) were kept in normoxic or hyperoxic environments for 15 min prior to harvesting the heart and Langendorff perfusion with global ischemia (45 min) and reperfusion (60 min). Endpoints were cardiac function and infarct size. Additional hearts were collected to evaluate MAPK phosphorylation (immunoblot). The nitric oxide synthase inhibitor L-NAME, the ERK1/2 inhibitor PD98059 and the p38 MAPK inhibitor FR167653 were injected intraperitoneally before hyperoxia or normoxia. Hyperoxia improved postischemic functional recovery and reduced infarct size (p < 0.05). Hyperoxic exposure caused cardiac phosphorylation of the MAPK family members p38 and ERK1/2, but not JNK. L-NAME, PD98059 and FR167653 all reduced the protection afforded by hyperoxic exposure, but did not influence performance or infarction in hearts of normoxic mice. The hyperoxia-induced phosphorylation of ERK1/2 and p38 was reduced by L-NAME and both MAPK inhibitors. Nitric oxide triggers hyperoxic protection, and ERK1/2 and p38 MAPK are involved in signaling of protection against ischemia-reperfusion injury.
doi_str_mv 10.1007/s00395-007-0644-5
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70610457</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70610457</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-50dc571fb683111661c448d109d10986421159683d99c1dac37d5531e981880d3</originalsourceid><addsrcrecordid>eNpdkUFvEzEQhS0EoqHwA7ggi0NvS2fW9q73iKoWkIq4wNly7EnidmMHezdqbvz0OiQSEofRjDTfvKfRY-w9wicE6K8LgBhUU8cGOikb9YItUArVoAbxki1AADRatvqCvSnlAQBl1-FrdoF922mt1YL9-X5IzmYf7Mh3OU3kppAip316JM-XB7457Cinp-A4Pe1SmTPxEPdp3FPhJayjHUNc82mT07ze8BimXNHKe-I2er4NU1pT5Lbq7u1UNf-6hMgfQ7SFylv2amXHQu_O_ZL9urv9efO1uf_x5dvN5_vGibabGgXeqR5Xy04LRKxvOCm1RxiOpTvZIqqhLv0wOPTWid4rJZAGjVqDF5fs6qRb_X_PVCazDcXRONpIaS6mhw5Bqr6CH_8DH9Kc65_FtChQIQisEJ4gl1MpmVZml8PW5oNBMMdszCkbcxyP2RhVbz6chefllvy_i3MY4hntVYs6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213151031</pqid></control><display><type>article</type><title>Myocardial protection evoked by hyperoxic exposure involves signaling through nitric oxide and mitogen activated protein kinases</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Ruusalepp, Arno ; Czibik, Gabor ; Flatebø, Torun ; Vaage, Jarle ; Valen, Guro</creator><creatorcontrib>Ruusalepp, Arno ; Czibik, Gabor ; Flatebø, Torun ; Vaage, Jarle ; Valen, Guro</creatorcontrib><description>Hyperoxic exposure in vivo (&gt; 95% oxygen) attenuates ischemia-reperfusion injury, but the signaling mechanisms of this cardioprotection are not fully determined. We studied a possible role of nitric oxide (NO) and mitogen activated protein kinases (MAPK) in hyperoxic protection. Mice (n = 7-9 in each group) were kept in normoxic or hyperoxic environments for 15 min prior to harvesting the heart and Langendorff perfusion with global ischemia (45 min) and reperfusion (60 min). Endpoints were cardiac function and infarct size. Additional hearts were collected to evaluate MAPK phosphorylation (immunoblot). The nitric oxide synthase inhibitor L-NAME, the ERK1/2 inhibitor PD98059 and the p38 MAPK inhibitor FR167653 were injected intraperitoneally before hyperoxia or normoxia. Hyperoxia improved postischemic functional recovery and reduced infarct size (p &lt; 0.05). Hyperoxic exposure caused cardiac phosphorylation of the MAPK family members p38 and ERK1/2, but not JNK. L-NAME, PD98059 and FR167653 all reduced the protection afforded by hyperoxic exposure, but did not influence performance or infarction in hearts of normoxic mice. The hyperoxia-induced phosphorylation of ERK1/2 and p38 was reduced by L-NAME and both MAPK inhibitors. Nitric oxide triggers hyperoxic protection, and ERK1/2 and p38 MAPK are involved in signaling of protection against ischemia-reperfusion injury.</description><identifier>ISSN: 0300-8428</identifier><identifier>EISSN: 1435-1803</identifier><identifier>DOI: 10.1007/s00395-007-0644-5</identifier><identifier>PMID: 17268885</identifier><language>eng</language><publisher>Germany: Springer Nature B.V</publisher><subject>Animals ; Coronary Circulation ; Enzyme Inhibitors - pharmacology ; Flavonoids - pharmacology ; Hyperoxia - enzymology ; Hyperoxia - metabolism ; Hyperoxia - pathology ; Hyperoxia - physiopathology ; Male ; Mice ; Mice, Inbred C57BL ; Mitogen-Activated Protein Kinase 1 - metabolism ; Mitogen-Activated Protein Kinase 3 - metabolism ; Mitogen-Activated Protein Kinases - antagonists &amp; inhibitors ; Mitogen-Activated Protein Kinases - metabolism ; Myocardial Infarction - enzymology ; Myocardial Infarction - metabolism ; Myocardial Infarction - physiopathology ; Myocardial Infarction - prevention &amp; control ; Myocardial Reperfusion Injury - enzymology ; Myocardial Reperfusion Injury - metabolism ; Myocardial Reperfusion Injury - pathology ; Myocardial Reperfusion Injury - physiopathology ; Myocardial Reperfusion Injury - prevention &amp; control ; Myocardium - enzymology ; Myocardium - metabolism ; Myocardium - pathology ; NG-Nitroarginine Methyl Ester - pharmacology ; Nitric Oxide - metabolism ; Nitric Oxide Synthase - antagonists &amp; inhibitors ; Nitric Oxide Synthase - metabolism ; p38 Mitogen-Activated Protein Kinases - metabolism ; Phosphorylation ; Pyrazoles - pharmacology ; Pyridines - pharmacology ; Signal Transduction - drug effects ; Ventricular Function, Left ; Ventricular Pressure</subject><ispartof>Basic research in cardiology, 2007-07, Vol.102 (4), p.318-326</ispartof><rights>Steinkopff-Verlag 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c326t-50dc571fb683111661c448d109d10986421159683d99c1dac37d5531e981880d3</citedby><cites>FETCH-LOGICAL-c326t-50dc571fb683111661c448d109d10986421159683d99c1dac37d5531e981880d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17268885$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ruusalepp, Arno</creatorcontrib><creatorcontrib>Czibik, Gabor</creatorcontrib><creatorcontrib>Flatebø, Torun</creatorcontrib><creatorcontrib>Vaage, Jarle</creatorcontrib><creatorcontrib>Valen, Guro</creatorcontrib><title>Myocardial protection evoked by hyperoxic exposure involves signaling through nitric oxide and mitogen activated protein kinases</title><title>Basic research in cardiology</title><addtitle>Basic Res Cardiol</addtitle><description>Hyperoxic exposure in vivo (&gt; 95% oxygen) attenuates ischemia-reperfusion injury, but the signaling mechanisms of this cardioprotection are not fully determined. We studied a possible role of nitric oxide (NO) and mitogen activated protein kinases (MAPK) in hyperoxic protection. Mice (n = 7-9 in each group) were kept in normoxic or hyperoxic environments for 15 min prior to harvesting the heart and Langendorff perfusion with global ischemia (45 min) and reperfusion (60 min). Endpoints were cardiac function and infarct size. Additional hearts were collected to evaluate MAPK phosphorylation (immunoblot). The nitric oxide synthase inhibitor L-NAME, the ERK1/2 inhibitor PD98059 and the p38 MAPK inhibitor FR167653 were injected intraperitoneally before hyperoxia or normoxia. Hyperoxia improved postischemic functional recovery and reduced infarct size (p &lt; 0.05). Hyperoxic exposure caused cardiac phosphorylation of the MAPK family members p38 and ERK1/2, but not JNK. L-NAME, PD98059 and FR167653 all reduced the protection afforded by hyperoxic exposure, but did not influence performance or infarction in hearts of normoxic mice. The hyperoxia-induced phosphorylation of ERK1/2 and p38 was reduced by L-NAME and both MAPK inhibitors. Nitric oxide triggers hyperoxic protection, and ERK1/2 and p38 MAPK are involved in signaling of protection against ischemia-reperfusion injury.</description><subject>Animals</subject><subject>Coronary Circulation</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Flavonoids - pharmacology</subject><subject>Hyperoxia - enzymology</subject><subject>Hyperoxia - metabolism</subject><subject>Hyperoxia - pathology</subject><subject>Hyperoxia - physiopathology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Mitogen-Activated Protein Kinase 1 - metabolism</subject><subject>Mitogen-Activated Protein Kinase 3 - metabolism</subject><subject>Mitogen-Activated Protein Kinases - antagonists &amp; inhibitors</subject><subject>Mitogen-Activated Protein Kinases - metabolism</subject><subject>Myocardial Infarction - enzymology</subject><subject>Myocardial Infarction - metabolism</subject><subject>Myocardial Infarction - physiopathology</subject><subject>Myocardial Infarction - prevention &amp; control</subject><subject>Myocardial Reperfusion Injury - enzymology</subject><subject>Myocardial Reperfusion Injury - metabolism</subject><subject>Myocardial Reperfusion Injury - pathology</subject><subject>Myocardial Reperfusion Injury - physiopathology</subject><subject>Myocardial Reperfusion Injury - prevention &amp; control</subject><subject>Myocardium - enzymology</subject><subject>Myocardium - metabolism</subject><subject>Myocardium - pathology</subject><subject>NG-Nitroarginine Methyl Ester - pharmacology</subject><subject>Nitric Oxide - metabolism</subject><subject>Nitric Oxide Synthase - antagonists &amp; inhibitors</subject><subject>Nitric Oxide Synthase - metabolism</subject><subject>p38 Mitogen-Activated Protein Kinases - metabolism</subject><subject>Phosphorylation</subject><subject>Pyrazoles - pharmacology</subject><subject>Pyridines - pharmacology</subject><subject>Signal Transduction - drug effects</subject><subject>Ventricular Function, Left</subject><subject>Ventricular Pressure</subject><issn>0300-8428</issn><issn>1435-1803</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkUFvEzEQhS0EoqHwA7ggi0NvS2fW9q73iKoWkIq4wNly7EnidmMHezdqbvz0OiQSEofRjDTfvKfRY-w9wicE6K8LgBhUU8cGOikb9YItUArVoAbxki1AADRatvqCvSnlAQBl1-FrdoF922mt1YL9-X5IzmYf7Mh3OU3kppAip316JM-XB7457Cinp-A4Pe1SmTPxEPdp3FPhJayjHUNc82mT07ze8BimXNHKe-I2er4NU1pT5Lbq7u1UNf-6hMgfQ7SFylv2amXHQu_O_ZL9urv9efO1uf_x5dvN5_vGibabGgXeqR5Xy04LRKxvOCm1RxiOpTvZIqqhLv0wOPTWid4rJZAGjVqDF5fs6qRb_X_PVCazDcXRONpIaS6mhw5Bqr6CH_8DH9Kc65_FtChQIQisEJ4gl1MpmVZml8PW5oNBMMdszCkbcxyP2RhVbz6chefllvy_i3MY4hntVYs6</recordid><startdate>20070701</startdate><enddate>20070701</enddate><creator>Ruusalepp, Arno</creator><creator>Czibik, Gabor</creator><creator>Flatebø, Torun</creator><creator>Vaage, Jarle</creator><creator>Valen, Guro</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20070701</creationdate><title>Myocardial protection evoked by hyperoxic exposure involves signaling through nitric oxide and mitogen activated protein kinases</title><author>Ruusalepp, Arno ; Czibik, Gabor ; Flatebø, Torun ; Vaage, Jarle ; Valen, Guro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-50dc571fb683111661c448d109d10986421159683d99c1dac37d5531e981880d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Animals</topic><topic>Coronary Circulation</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Flavonoids - pharmacology</topic><topic>Hyperoxia - enzymology</topic><topic>Hyperoxia - metabolism</topic><topic>Hyperoxia - pathology</topic><topic>Hyperoxia - physiopathology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Mitogen-Activated Protein Kinase 1 - metabolism</topic><topic>Mitogen-Activated Protein Kinase 3 - metabolism</topic><topic>Mitogen-Activated Protein Kinases - antagonists &amp; inhibitors</topic><topic>Mitogen-Activated Protein Kinases - metabolism</topic><topic>Myocardial Infarction - enzymology</topic><topic>Myocardial Infarction - metabolism</topic><topic>Myocardial Infarction - physiopathology</topic><topic>Myocardial Infarction - prevention &amp; control</topic><topic>Myocardial Reperfusion Injury - enzymology</topic><topic>Myocardial Reperfusion Injury - metabolism</topic><topic>Myocardial Reperfusion Injury - pathology</topic><topic>Myocardial Reperfusion Injury - physiopathology</topic><topic>Myocardial Reperfusion Injury - prevention &amp; control</topic><topic>Myocardium - enzymology</topic><topic>Myocardium - metabolism</topic><topic>Myocardium - pathology</topic><topic>NG-Nitroarginine Methyl Ester - pharmacology</topic><topic>Nitric Oxide - metabolism</topic><topic>Nitric Oxide Synthase - antagonists &amp; inhibitors</topic><topic>Nitric Oxide Synthase - metabolism</topic><topic>p38 Mitogen-Activated Protein Kinases - metabolism</topic><topic>Phosphorylation</topic><topic>Pyrazoles - pharmacology</topic><topic>Pyridines - pharmacology</topic><topic>Signal Transduction - drug effects</topic><topic>Ventricular Function, Left</topic><topic>Ventricular Pressure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ruusalepp, Arno</creatorcontrib><creatorcontrib>Czibik, Gabor</creatorcontrib><creatorcontrib>Flatebø, Torun</creatorcontrib><creatorcontrib>Vaage, Jarle</creatorcontrib><creatorcontrib>Valen, Guro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Basic research in cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ruusalepp, Arno</au><au>Czibik, Gabor</au><au>Flatebø, Torun</au><au>Vaage, Jarle</au><au>Valen, Guro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Myocardial protection evoked by hyperoxic exposure involves signaling through nitric oxide and mitogen activated protein kinases</atitle><jtitle>Basic research in cardiology</jtitle><addtitle>Basic Res Cardiol</addtitle><date>2007-07-01</date><risdate>2007</risdate><volume>102</volume><issue>4</issue><spage>318</spage><epage>326</epage><pages>318-326</pages><issn>0300-8428</issn><eissn>1435-1803</eissn><abstract>Hyperoxic exposure in vivo (&gt; 95% oxygen) attenuates ischemia-reperfusion injury, but the signaling mechanisms of this cardioprotection are not fully determined. We studied a possible role of nitric oxide (NO) and mitogen activated protein kinases (MAPK) in hyperoxic protection. Mice (n = 7-9 in each group) were kept in normoxic or hyperoxic environments for 15 min prior to harvesting the heart and Langendorff perfusion with global ischemia (45 min) and reperfusion (60 min). Endpoints were cardiac function and infarct size. Additional hearts were collected to evaluate MAPK phosphorylation (immunoblot). The nitric oxide synthase inhibitor L-NAME, the ERK1/2 inhibitor PD98059 and the p38 MAPK inhibitor FR167653 were injected intraperitoneally before hyperoxia or normoxia. Hyperoxia improved postischemic functional recovery and reduced infarct size (p &lt; 0.05). Hyperoxic exposure caused cardiac phosphorylation of the MAPK family members p38 and ERK1/2, but not JNK. L-NAME, PD98059 and FR167653 all reduced the protection afforded by hyperoxic exposure, but did not influence performance or infarction in hearts of normoxic mice. The hyperoxia-induced phosphorylation of ERK1/2 and p38 was reduced by L-NAME and both MAPK inhibitors. Nitric oxide triggers hyperoxic protection, and ERK1/2 and p38 MAPK are involved in signaling of protection against ischemia-reperfusion injury.</abstract><cop>Germany</cop><pub>Springer Nature B.V</pub><pmid>17268885</pmid><doi>10.1007/s00395-007-0644-5</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0300-8428
ispartof Basic research in cardiology, 2007-07, Vol.102 (4), p.318-326
issn 0300-8428
1435-1803
language eng
recordid cdi_proquest_miscellaneous_70610457
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Animals
Coronary Circulation
Enzyme Inhibitors - pharmacology
Flavonoids - pharmacology
Hyperoxia - enzymology
Hyperoxia - metabolism
Hyperoxia - pathology
Hyperoxia - physiopathology
Male
Mice
Mice, Inbred C57BL
Mitogen-Activated Protein Kinase 1 - metabolism
Mitogen-Activated Protein Kinase 3 - metabolism
Mitogen-Activated Protein Kinases - antagonists & inhibitors
Mitogen-Activated Protein Kinases - metabolism
Myocardial Infarction - enzymology
Myocardial Infarction - metabolism
Myocardial Infarction - physiopathology
Myocardial Infarction - prevention & control
Myocardial Reperfusion Injury - enzymology
Myocardial Reperfusion Injury - metabolism
Myocardial Reperfusion Injury - pathology
Myocardial Reperfusion Injury - physiopathology
Myocardial Reperfusion Injury - prevention & control
Myocardium - enzymology
Myocardium - metabolism
Myocardium - pathology
NG-Nitroarginine Methyl Ester - pharmacology
Nitric Oxide - metabolism
Nitric Oxide Synthase - antagonists & inhibitors
Nitric Oxide Synthase - metabolism
p38 Mitogen-Activated Protein Kinases - metabolism
Phosphorylation
Pyrazoles - pharmacology
Pyridines - pharmacology
Signal Transduction - drug effects
Ventricular Function, Left
Ventricular Pressure
title Myocardial protection evoked by hyperoxic exposure involves signaling through nitric oxide and mitogen activated protein kinases
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T18%3A26%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Myocardial%20protection%20evoked%20by%20hyperoxic%20exposure%20involves%20signaling%20through%20nitric%20oxide%20and%20mitogen%20activated%20protein%20kinases&rft.jtitle=Basic%20research%20in%20cardiology&rft.au=Ruusalepp,%20Arno&rft.date=2007-07-01&rft.volume=102&rft.issue=4&rft.spage=318&rft.epage=326&rft.pages=318-326&rft.issn=0300-8428&rft.eissn=1435-1803&rft_id=info:doi/10.1007/s00395-007-0644-5&rft_dat=%3Cproquest_cross%3E70610457%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213151031&rft_id=info:pmid/17268885&rfr_iscdi=true